title: Changed purine nucleotide concentrations and enzyme activities in erythrocytes of haemodialysis patients undergoing erythropoietin therapy.
abstract: Therapy of renal anaemia in haemodialysis patients with chronic renal failure by application of recombinant human erythropoietin leads to an increase of the haematocrit. Rejuvenation of the erythrocyte population results in a decrease of the median density (D50), an increase of cell age-dependent enzyme activities, such as aspartate aminotransferase, and elevated concentrations of purine nucleotides in the erythrocytes. After density gradient separation of erythrocyte populations into cell age-dependent fractions, the concentrations of adenosine-5'-triphosphate, guanosine-5'-triphosphate and guanosine-5'-diphosphate were be found to be elevated by 25-100% in all cell fractions from haemodialysis patients, compared with a healthy control group. Therapy of haemodialysis patients with recombinant human erythropoietin leads to further increase (65%) of ATP in the younger (low density) cells, but not in the older (high density) cells. The elevated concentrations of ATP and total adenine nucleotides during recombinant human erythropoietin therapy possibly result in improved deformability of erythrocytes. The data point to an enhancement of the proportion of younger erythrocytes, but not to an improvement of the reduced life span of erythrocytes of haemodialysis patients during therapy with recombinant human erythropoietin.
authors.affiliation: Institut für Biochemie, Charité, Humboldt-Universität zu Berlin.
authors.forename: W
authors.initials: W
authors.lastname: Siems
authors.forename: T
authors.initials: T
authors.lastname: Grune
authors.forename: H
authors.initials: H
authors.lastname: Hampl
authors.forename: G
authors.initials: G
authors.lastname: Wendel
authors.forename: G
authors.initials: G
authors.lastname: Gerber
authors.forename: E
authors.initials: E
authors.lastname: Riedel
mesh_terms: D000244:Adenosine Diphosphate / Q000378:metabolism; D000249:Adenosine Monophosphate / Q000378:metabolism; D000255:Adenosine Triphosphate / Q000378:metabolism; D000328:Adult; D000368:Aged; D001219:Aspartate Aminotransferases / Q000097:blood*; D004912:Erythrocytes / Q000187:drug effects / Q000201:enzymology*; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006153:Guanosine Diphosphate / Q000378:metabolism; D006160:Guanosine Triphosphate / Q000378:metabolism; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011685:Purine Nucleotides / Q000097:blood*; D006435:Renal Dialysis
chemical_list: D011685:Purine Nucleotides; D004921:Erythropoietin; D006153:Guanosine Diphosphate; D000249:Adenosine Monophosphate; D000244:Adenosine Diphosphate; D006160:Guanosine Triphosphate; D000255:Adenosine Triphosphate; D001219:Aspartate Aminotransferases